GWM
CSCI

Graybill Wealth Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Graybill Wealth Management’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$141 – 189
2025
Q1 		$141 Buy
+50
New +$147 ﹤0.01% 187

Other funds holding CSCI

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Graybill Wealth Management's CSCI Position: Q2 2025 in Review

Graybill Wealth Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q2 2025, closing a stake of 50 shares — an estimated $141 sold.

Graybill Wealth Management first reported a position in CSCI in Q1 2025 and held it in 1 quarter. The position peaked at $141 in Q1 2025. 15 funds tracked by Wall St. Rank hold CSCI as of Q2 2025.

  • Graybill Wealth Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • Graybill Wealth Management sold 50 COSCIENS Biopharma Inc. Common Stock shares in Q2 2025, an estimated $141.
  • Graybill Wealth Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q1 2025 and held it in 1 quarter.
  • Graybill Wealth Management's COSCIENS Biopharma Inc. Common Stock position peaked at $141 in Q1 2025.
  • 15 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q2 2025.

Based on Graybill Wealth Management's 13F filing for Q2 2025, filed 31 Jul 2025.